Australia markets closed

Coloplast A/S (CLPBY)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
15.55+0.19 (+1.24%)
At close: 3:57PM EST
Full screen
Trade prices are not sourced from all markets
Previous close15.36
Bid0.00 x 0
Ask0.00 x 0
Day's range15.48 - 15.79
52-week range14.40 - 17.04
Avg. volume92,045
Market cap32.972B
Beta (5Y monthly)0.07
PE ratio (TTM)54.94
EPS (TTM)0.28
Earnings dateN/A
Forward dividend & yield0.28 (1.83%)
Ex-dividend date04 Dec 2020
1y target estN/A
  • Coloplast A/S - Announcement no. 02/2021 - Share Buyback Programme

    Coloplast A/S - Announcement no. 02/2021 - Share Buyback Programme

    Coloplast A/S (“Coloplast” or the “Company”) is initiating a share buyback programme totalling up to DKK 500 million, as announced in the Company Announcement no. 01/2021 of 2 February 2021. The programme will commence on 22 February 2021 and is expected to end by 23 August 2021. The share buy-back programme is being launched within the authority granted by the shareholders at the Annual General Meeting on 5 December 2019, for the repurchase of up to 10% of the Company’s share capital, provided that the Company’s total holding of treasury shares does not exceed 10% of the Company’s share capital at any time. The share buyback programme is carried out in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour Regulations with the purpose of meeting obligations arising from share options programmes or other allocation of shares to employees or to complete a share capital decrease as set out in Articles 5(2)(a) and 5(2)(c) in MAR. The Company has retained Danske Bank A/S (“Danske Bank”) to act as manager of the share buyback programme and purchase shares on behalf of Coloplast. Danske Bank has also agreed under the contract to make its trading decisions in relation to the shares in the Company independently of, and without influence by, the Company. Coloplast is entitled to discontinue the share buyback programme at any time. If the Company decides to discontinue the programme, such a decision will be disclosed to the public through a company announcement. If discontinued, Danske Bank will no longer be entitled to purchase shares in Coloplast on behalf of the Company. The DKK 500 million share buyback programme is subject to the following terms: The programme will commence on 22 February 2021 and is expected to end by 23 August 2021. The volume of trading in own shares will be limited to a maximum total market value of DKK 500 million. The maximum number of shares to be purchased in the Company per daily market session will be the equivalent to 25% of the average volume of shares in the Company traded on Nasdaq Copenhagen A/S during the preceding 20 trading days.During the life of the share buyback programme no shares will be purchased at a price exceeding the higher of the following two prices: i) the price of the last independent trade on Nasdaq Copenhagen A/S and ii) the highest current independent bid on Nasdaq Copenhagen A/S. Details of transactions executed under the share buyback programme will be disclosed to the market in accordance with the Safe Harbour Regulation and will be publicly disclosed on the company’s website at least once every seventh trading day. Prior to the launch of the share buyback programme Coloplast A/S holds 3,038,288 treasury shares, equal to 1.41% of the company’s share capital. For further information, please contact Investors and analystsAnders Lonning-SkovgaardExecutive Vice President, CFOTel. +45 4911 1111 Ellen BjurgertVice President, Investor RelationsTel. +45 4911 1800 /+45 4911 3376Email: Press and mediaPeter MønsterSr. Media Relations ManagerTel. +45 4911 2623Email: AddressColoplast A/SHoltedam 1DK-3050 HumlebaekDenmarkCompany reg. (CVR) no. 69749917 This announcement is available in a Danish and an English-language version. In the event of discrepancies, the Danish version shall prevail. Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate health care. Our business includes Ostomy Care, Continence Care, Wound and Skin Care and Interventional Urology. We operate globally and employ about 12,500 employees. The Coloplast logo is a registered trademark of Coloplast A/S. © 2021-02. All rights reserved Coloplast A/S, 3050 Humlebaek, Denmark. Attachment 02_2021_Share_Buyback_Programme

  • Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons

    Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons

    Please see enclosed pdf. Attachment 15022021_trading_in_shares_LRA

  • Coloplast delivers a good start to the year with 5% organic growth in Q1 and maintains its financial guidance for 2020/21

    Coloplast delivers a good start to the year with 5% organic growth in Q1 and maintains its financial guidance for 2020/21

    Coloplast delivered 5% organic growth, and EBIT increased by 4% to DKK 1,536m, corresponding to an EBIT margin of 32%, in the first quarter of the 2020/21 financial year. The company maintains its financial guidance for 2020/21. Coloplast delivered 5% organic revenue growth in the first three months of the 2020/21 financial year. EBIT amounted to DKK 1,536m, a 4% increase, corresponding to an EBIT-margin of 32% against 31% last year. “Our priorities have been clear throughout the pandemic. We want to keep our employees safe, while continuing to serve our customers, who rely on our products and services to manage their conditions. I am proud of the work that is being done by our many teams across the world to make sure that we continue business operations and continue to support our customers,” says Coloplast CEO Kristian Villumsen and continues: “Despite the COVID-19 outbreak, we deliver a solid set of results in Q1. We continue to deliver organic growth across all geographical regions and business areas, which means that more and more people with personal medical conditions are getting the help and support they need to lead better lives.” “I would like to highlight our solid performance in the US as well as our strong momentum in Emerging Markets, particularly driven by growth in China, Latin America and tender deliveries in Russia. Also, our Interventional Urology business delivered a good quarter driven by the Men’s Health portfolio in the US, which returned to growth as elective procedures continued to recover during the quarter.” Organic growth rates by business area were 6% in Ostomy Care, 6% in Continence Care, 5% in Interventional Urology, and 1% in Wound & Skin Care. Wound Care in isolation delivered 5% organic growth driven by Europe and a return to growth in China. The recently launched Biatain® Fiber portfolio contributed positively to growth, driven by France and Germany. Looking at sales by geography, the European markets contributed with 2% growth, Other developed markets delivered 7% revenue growth, while Emerging Markets provided a 16% increase. Growth in Europe continues to be negatively impacted by the COVID-19 outbreak due to lower growth in new patients, particularly in the UK Chronic Care business. While Coloplast delivered 5% organic growth, reported growth in Danish kroner was up by 1% to DKK 4,738m. Reported revenue was, as expected, adversely affected by the depreciation of USD, GBP, and several emerging markets currencies, especially ARS and BRL. ROIC after tax and before special items was 44% against 47% in the same period last year impacted by the acquisition of Nine Continents Medical in November 2020. The COVID-19 pandemic Coloplast continues to monitor developments closely across all markets and continues to take all necessary precautionary measures to comply with and support local, national, and global guidelines from healthcare authorities. The company’s global manufacturing sites are operating at normal capacity in terms of production and supply chain, and the company continues to fully meet customer demand. Coloplast continues to invest in innovation and growthColoplast continues to move forward with its new corporate strategy “Strive25 – Sustainable Growth Leadership” and yearly invest up to 2% of revenue in innovation and commercial initiatives to drive growth. So far this financial year, the company has invested in sales and marketing activities in Asia, consumer and digital initiatives, innovation, and Interventional Urology. Financial guidance for 2020/21In line with its long-term guidance Coloplast continues to guide for 7-8% organic revenue growth and a reported growth in DKK of 4-5%. Coloplast continues to expect a reported EBIT margin in DKK of 31-32%. The guidance reflects additional incremental investments and continued prudent cost management. Capital expenditure is still expected to be DKK ~1.1bn. The effective tax rate is still expected to be ~23%. CONTACTSPeter MønsterSenior Media Relations Manager, Corporate Communications+45 49 11 26 Ellen BjurgertVice President, Investor Relations+45 49 11 33 Financial highlights and key ratios DKKm2020/21 – Q1 2019/20 – Q1 ChangeRevenue4,7384,7125%EBIT1,5361,4724%EBIT margin32%31%1%-ptsNet profit for the period1,1361,0924% Sales performance by business area DKKm2020/21 - Q12019/20 - Q1Organic growthReported growthOstomy Care1,9321,9076%1%Continence Care1,7051,6866%1%Interventional Urology5365355%0%Wound & Skin Care5655841%-3%Net revenue4,7384,7125%1% Sales performance by region DKKm2021/21 – Q12019/20 – Q1Organic growthReported growthEuropean markets2,7372,7442%0%Other developed markets1,1741,1787%0%Emerging Markets82779016%5%Net revenue4,7384,7125%1% Attachment 2020_2021_Q1_PM_ENG